纽约州将卵巢癌肿瘤细胞减灭术集中至高容量中心及其对患者出行的影响
基于纽约州癌症登记和全州规划研究合作系统,回顾性分析2004年1月1日至2018年12月31日接受肿瘤细胞减灭术的卵巢癌患者,按年手术量<21例和≥21例分为低容量和高容量中心,模拟集中化对患者驾车距离和时间的影响。结果显示集中化后多数患者出行负担增加甚微。
要点
- 2004年至2018年纽约州210家机构中,159家(75.7%)为低容量中心,51家(24.3%)为高容量中心。
- 高容量中心患者驾车中位距离12.2英里、时间23.0分钟,低容量中心分别为8.2英里、16.8分钟。
- 若将手术集中至高容量中心,原低容量中心患者的中位距离和时间将变为11.2英里和20.2分钟。
核心结论
- 在纽约州将卵巢癌肿瘤细胞减灭术集中至高容量中心,对多数患者而言出行距离和时间增加甚微。
研究设计与样本
- 回顾性研究,数据来自纽约州癌症登记和全州规划研究合作系统,纳入2004年1月1日至2018年12月31日接受肿瘤细胞减灭术的卵巢癌患者60,493例。
- 医院按年卵巢癌肿瘤细胞减灭术量分为低容量中心(<21例/年)和高容量中心(≥21例/年),并进行模拟分析。
主要发现
- 2004年至2018年,纽约州210家机构中159家(75.7%)为低容量中心,51家(24.3%)为高容量中心。
- 10,514例(17.4%)患者在低容量中心治疗,49,979例(82.6%)在高容量中心治疗。
- 2004年78.2%的患者在高容量中心治疗,2018年增至84.6%(P < .0001)。
- 高容量中心患者驾车中位距离12.2英里(IQR,5.6-25.5)、时间23.0分钟(IQR,15.2-37.0);低容量中心分别为8.2英里(IQR,3.7-15.9)和16.8分钟(IQR,12.4-26.0)。
- 若集中至高容量中心,原低容量中心患者的中位距离和时间将为11.2英里(IQR,3.8-32.3;P < .001)和20.2分钟(IQR,13.6-43.0;P < .001)。
临床怎么用
- 原文结论认为集中化对多数患者出行负担增加甚微,未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the theoretical impact of regionalizing cytoreductive surgery for ovarian cancer (OC) to high-volume facilities on patient travel. METHODS: We retrospectively identified patients with OC who underwent cytoreduction between 1/1/2004-12/31/2018 from the New York State Cancer Registry and Statewide Planning and Research Cooperative System. Hospitals were stratified by low-volume (<21 cytoreductive surgical procedures for OC annually) and high-volume centers (≥21 procedures annually). A simulation was performed; outcomes of interest were driving distance and time between the centroid of the patient's residence zip code and the treating facility zip code. RESULTS: Overall, 60,493 patients met inclusion criteria. Between 2004 and 2018, 210 facilities were performing cytoreductive surgery for OC in New York; 159 facilities (75.7%) met low-volume and 51 (24.3%) met high-volume criteria. Overall, 10,514 patients (17.4%) were treated at low-volume and 49,979 (82.6%) at high-volume facilities. In 2004, 78.2% of patients were treated at high-volume facilities, which increased to 84.6% in 2018 (P < .0001). Median travel distance and time for patients treated at high-volume centers was 12.2 miles (IQR, 5.6-25.5) and 23.0 min (IQR, 15.2-37.0), and 8.2 miles (IQR, 3.7-15.9) and 16.8 min (IQR, 12.4-26.0) for patients treated at low-volume centers. If cytoreductive surgery was centralized to high-volume centers, median distance and time traveled for patients originally treated at low-volume centers would be 11.2 miles (IQR, 3.8-32.3; P < .001) and 20.2 min (IQR, 13.6-43.0; P < .001). CONCLUSIONS: Centralizing cytoreductive surgery for OC to high-volume centers in New York would increase patient travel burden by negligible amounts of distance and time for most patients.
引用
- Kahn RM, Ma X, Gordhandas S, et al. Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State. Gynecol Oncol. 2024. PMID: 38262237. doi:10.1016/j.ygyno.2024.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。